Company Profile
Lyell Immunopharma Stock Price, News & Analysis
Company overview
Business overview
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Lyell Immunopharma is followed within the immunology universe for its exposure to chronic-disease treatment demand and catalyst-driven clinical updates.
Business Model Characteristics
Lyell Immunopharma is a pipeline-led immunology story, so the market tends to track readouts, regulatory milestones, and how the company expands from one immune program to the next.
Position Within the Biotechnology Landscape
Compared with more mature peers, Lyell Immunopharma sits close to the development side of the biotech landscape, where immunology data can change sentiment quickly.
Why the stock is moving
LYEL is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Lyell has a lot riding on its CAR-T programs, especially ronde-cel in the head-to-head Phase 3 trial. The dosing that has already started in PiNACLE-H2H and the ongoing 3L+ pivotal study give the company real clinical signposts, while LYL273 keeps the platform story from being just one asset.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
Source: Lyell Immunopharma
- 02
- 03
- 04
- 05
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Source: Lyell Immunopharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.